Drug Database
Back to search

Poland· PL-100108639

Fasturtec

A rasburicase product containing rasburicasum, registered in Poland by Sanofi Winthrop Industrie. The same ATC class is registered in 13 of our 19 countries.

ATC V03AF07

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedFasturtecATCV03AF07REGISTER NO.PL-100108639PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about rasburicasumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Rasburicase is registered in 13 of 19 countries.

Countries holding a registration under ATC V03AF07 (rasburicase), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose
Search rasburicase products by name

Rasburicase · ATC V03AF07

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Rasburicasum
Manufacturer
Sanofi Winthrop Industrie
Country
Poland (PL)
ATC code
V03AF07
ATC class
Rasburicase
Defined daily dose
14 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909990943111
  • gtin
    05909990943128

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

25 interactions on record for rasburicase.

Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check rasburicase against other medicinesHow interaction checks work

Rasburicase · interactions on record

25 records

  • 1 severe
  • 24 moderate

Most severe, free to view

  • PrilocaineN01BB04severe
  • LidocainA01AE01moderate
  • TetracainA01AE02moderate
  • LidocaineC05AD01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Rasburicase in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All rasburicase products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Fasturtec
  • Liechtenstein · Fasturtec
  • Norway · Fasturtec

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b8da4184-9927-4c60-a274-0fb24671d3bd
GET /v1/drugs/b8da4184-9927-4c60-a274-0fb24671d3bd?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Proszek i rozpuszczalnik do sporządzania koncentratu roztworu do infuzji",
  "source": "urpl",
  "strength": "1,5 mg/ml",
  "packaging": "05909990943111 ¦ Rpz ¦ EU/1/00/170/001 ¦ 19376\n3 fiol. 1,5 mg ¦ 3 amp.-strzyk. 2 ml\n¦ UR/Z/4c/030/23 - 05909990943111\n05909990943128 ¦ Rpz ¦ EU/1/00/170/002 ¦ 20211\n1 fiol. 7,5 mg ¦ 1 amp.-strzyk. 5 ml",
  "substance": "Rasburicasum 1.5 mg/ml",
  "common_name": "Rasburicasum",
  "pl_product_id": "100108639",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about rasburicase.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console